TY - CHAP
T1 - Liquid bead array technology in the detection of common translocations in acute and chronic leukemias
AU - Shackelford, Rodney E.
AU - Jackson, Keith D.
AU - Hafez, Michael J.
AU - Gocke, Christopher D.
N1 - Copyright:
Copyright 2021 Elsevier B.V., All rights reserved.
PY - 2013
Y1 - 2013
N2 - Hematologic malignancies often have specific chromosomal translocations that promote cancer initiation and progression. Translocation identification is often vital in the diagnosis, prognosis, and treatment of malignancies. A variety of methods including metaphase cytogenetics, in situ hybridization, microarray techniques, Southern blotting, and many variations of PCR are used to identify translocations. While all these techniques have utility, many have drawbacks limiting their clinical usefulness: high cost, slow turnaround time, low density, large sample requirements, high complexity, and difficult validation and standardization. Multiplexed RT-PCR combined with liquid bead array detection overcomes many of these limitations, allowing simultaneous amplification and detection of multiple translocations within one patient sample. This system has high reliability, reproducibility, and flexibility; low cost and low complexity; rapid turnaround time; and appropriate analyte density. Recently, Asuragen Inc. has developed a multiplexed RT-PCR liquid bead array panel that simultaneously analyzes 12 fusion transcripts found in four major types of hematologic malignancies, allowing rapid and efficient diagnosis. In this chapter, we review liquid bead array technology in relation to the specific hematologic translocations analyzed in the Signature LTx panel.
AB - Hematologic malignancies often have specific chromosomal translocations that promote cancer initiation and progression. Translocation identification is often vital in the diagnosis, prognosis, and treatment of malignancies. A variety of methods including metaphase cytogenetics, in situ hybridization, microarray techniques, Southern blotting, and many variations of PCR are used to identify translocations. While all these techniques have utility, many have drawbacks limiting their clinical usefulness: high cost, slow turnaround time, low density, large sample requirements, high complexity, and difficult validation and standardization. Multiplexed RT-PCR combined with liquid bead array detection overcomes many of these limitations, allowing simultaneous amplification and detection of multiple translocations within one patient sample. This system has high reliability, reproducibility, and flexibility; low cost and low complexity; rapid turnaround time; and appropriate analyte density. Recently, Asuragen Inc. has developed a multiplexed RT-PCR liquid bead array panel that simultaneously analyzes 12 fusion transcripts found in four major types of hematologic malignancies, allowing rapid and efficient diagnosis. In this chapter, we review liquid bead array technology in relation to the specific hematologic translocations analyzed in the Signature LTx panel.
KW - Acute lymphoblastic leukemia
KW - Acute myeloid leukemia
KW - Acute promyelocytic leukemia
KW - Chronic myelogenous leukemia
KW - Hematologic malignancy
KW - Liquid bead array
KW - PCR
KW - Translocation
UR - http://www.scopus.com/inward/record.url?scp=84883215975&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84883215975&partnerID=8YFLogxK
U2 - 10.1007/978-1-62703-357-2_6
DO - 10.1007/978-1-62703-357-2_6
M3 - Chapter
C2 - 23666692
AN - SCOPUS:84883215975
SN - 9781627033565
T3 - Methods in Molecular Biology
SP - 93
EP - 103
BT - Hematological Malignancies
PB - Humana Press Inc.
ER -